Ann: Application for quotation of securities - 4DX, page-65

I also agree with UberTrader.

You're making this forum turn into an echo chamber where positive sentiment gets amplified and negative sentiment gets criticised down to zero.

4DX has great potential with a really impactful technology but they have failed to execute anything meaningful (in terms of revenue) with pretty deep operational burn. This is okay and totally understandable for a MedTech company, but needs to be managed carefully. They have not managed this carefully and the result is they have time and time again had to raise funds and dilute existing shareholders.

I believe in the long-term (I've been holding since 2021) they definitely will succeed but if you think AF deserved to get a 60% raise YOY raise is crazy - I can't see why you guys are justifying it as a good thing. I've seen this before, the higher your salary the more you're de-risking yourself from the outcome of the business, so you're less aligned to see it through.

I think a good Australian MedTech business is ASX:EMV (I don't hold it), but they raise money and manage their operation a lot better than 4DX. They haven't done crazy dilution like 4DX.